While COVID-19 does not discriminate in infecting patients, the data actually shows that virus outcomes have disproportionately affected minority communities. Further, despite a focus on improving diversity in trials for the disease, the trials fell short of diversity goals. A new study looks at why and how biopharma companies can improve. This week we also ... READ MORE >
Life Sciences
The life sciences sector comprises some of the middle market’s fastest-growing companies. Whether developing life-saving new drugs or robotic components for surgery, this vibrant sector is a hotbed of innovation.
5 things to know in life sciences: Week of May 10
There are a few key milestones in the life cycle of a biopharma: raising your series A, starting your first clinical trial, going public and, for an increasing percent of companies, launching your first drug on your own. But developing a drug and successfully launching it requires different expertise and exposes the company to different risks. This week we ... READ MORE >
5 things to know in life sciences: Week of May 3
Public health experts are raising new concerns that achieving herd immunity in the United States looks increasingly unlikely. Although this doesn’t reduce the urgent need to get as many people vaccinated as possible, it does mean that we may need to begin planning for how we will live with COVID-19 as an endemic part of life. This week in our five things ... READ MORE >
5 things to know in life sciences: Week of April 26
Getting people vaccinated can be a public health challenge. Getting them to come back for a second dose at the right time can be even more difficult. This week we highlight why people may be skipping their second COVID-19 dose and how challenging getting that second dose can be even for people motivated to receive it. We also look at a Food and Drug ... READ MORE >
5 things to know in life sciences: Week of April 19
This week we look at comments from acting Food and Drug Administration commissioner Janet Woodcock on perceptions that the agency is getting tougher on drug companies during the approval process. We also highlight new uses of CRISPR to control gene expression, venture funds focused on life sciences, newly approved remote monitoring devices and a $17 billion ... READ MORE >
5 things to know in life sciences: Week of April 12
For the past few months, we've shared stories of positive developments in the race for COVID-19 vaccines and vaccinations. This week, we look at the long backstory of the challenges that have haunted the AstraZeneca vaccine efforts and why it is so critical for the world that these issues are resolved. We also look at the use of machine learning to improve ... READ MORE >
5 things to know in life sciences: Week of April 5
As the months of 2021 tick by, the percentage of Americans vaccinated is rapidly increasing. This offers the hope of a return to more normal life but also raises new questions, including whether companies can mandate vaccines or how we track the virus. We also look at the lack of diversity on the boards of life sciences companies, Food and Drug ... READ MORE >
5 things to know in life sciences: Week of March 29
Each week, we highlight five things you need to know about in the life sciences industry. Here’s the latest. 1. FTC challenges biopharma merger as antitrust scrutiny grows Less than two weeks after the Federal Trade Commission announced it would be taking a more stringent look at mergers in the biopharmaceutical industry, the proposed Illumina and Grail ... READ MORE >
CHART OF THE DAY: FTC challenges biopharma merger as antitrust scrutiny grows
Less than two weeks after the Federal Trade Commission announced it would be taking a more stringent look at mergers in the biopharmaceutical industry, the proposed Illumina and Grail merger became only the second vertical merger in 40 years (2017’s proposed merger between AT&T and Time Warner) to be legally challenged by the agency. The trial is ... READ MORE >
5 things to know in life sciences: Week of March 22
In this week’s life sciences roundup: the AstraZeneca-Oxford COVID-19 vaccine has faced challenging headwinds in the past week as several European Union countries paused distribution pending additional information from the European Medicines Agency, and as the National Institute of Allergy and Infectious Diseases in the United States publicly rebuked data ... READ MORE >